Abstract
Little is known about the roles of Rictor/mTORC2 in the leukemogenesis of acute myeloid leukemia. Here, we demonstrated that Rictor is essential for the maintenance of mixed lineage leukemia (MLL)-driven leukemia by preventing leukemia stem cells (LSCs) from exhaustion. Rictor depletion led to a reactive activation of mTORC1 signaling by facilitating the assembly of mTORC1. Hyperactivated mTORC1 signaling in turn drove LSCs into cycling, compromised the quiescence of LSCs and eventually exhausted their capacity to generate leukemia. At the same time, loss of Rictor had led to a reactive activation of FoxO3a in leukemia cells, which acts as negative feedback to restrain greater over-reactivation of mTORC1 activity and paradoxically protects leukemia cells from exhaustion. Simultaneous depletion of Rictor and FoxO3a enabled rapid exhaustion of MLL LSCs and a quick eradication of MLL leukemia. As such, our present findings highlighted a pivotal regulatory axis of Rictor-FoxO3a in maintaining quiescence and the stemness of LSCs.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Accession codes
References
Dick JE . Looking ahead in cancer stem cell research. Nat Biotechnol 2009; 27: 44–46.
Yeung J, Esposito MT, Gandillet A, Zeisig BB, Griessinger E, Bonnet D et al. beta-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells. Cancer Cell 2010; 18: 606–618.
Wang Y, Krivtsov AV, Sinha AU, North TE, Goessling W, Feng Z et al. The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science 2010; 327: 1650–1653.
Blackburn JS, Liu S, Wilder JL, Dobrinski KP, Lobbardi R, Moore FE et al. Clonal evolution enhances leukemia-propagating cell frequency in T cell acute lymphoblastic leukemia through Akt/mTORC1 pathway activation. Cancer Cell 2014; 25: 366–378.
Yilmaz OH, Valdez R, Theisen BK, Guo W, Ferguson DO, Wu H et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 2006; 441: 475–482.
Zhang J, Grindley JC, Yin T, Jayasinghe S, He XC, Ross JT et al. PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature 2006; 441: 518–522.
Sabatini DM . mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006; 6: 729–734.
Kalaitzidis D, Sykes SM, Wang Z, Punt N, Tang Y, Ragu C et al. mTOR complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesis. Cell Stem Cell 2012; 11: 429–439.
Hoshii T, Kasada A, Hatakeyama T, Ohtani M, Tadokoro Y, Naka K et al. Loss of mTOR complex 1 induces developmental blockage in early T-lymphopoiesis and eradicates T-cell acute lymphoblastic leukemia cells. Proc Natl Acad Sci USA 2014; 111: 3805–3810.
Tamburini J, Chapuis N, Bardet V, Park S, Sujobert P, Willems L et al. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Blood 2008; 111: 379–382.
Guertin DA, Sabatini DM . The pharmacology of mTOR inhibition. Sci Signal 2009; 2: pe24.
Hoshii T, Tadokoro Y, Naka K, Ooshio T, Muraguchi T, Sugiyama N et al. mTORC1 is essential for leukemia propagation but not stem cell self-renewal. J Clin Invest 2012; 122: 2114–2129.
Magee JA, Ikenoue T, Nakada D, Lee JY, Guan KL, Morrison SJ . Temporal changes in PTEN and mTORC2 regulation of hematopoietic stem cell self-renewal and leukemia suppression. Cell Stem Cell 2012; 11: 415–428.
Lee K, Nam KT, Cho SH, Gudapati P, Hwang Y, Park DS et al. Vital roles of mTOR complex 2 in Notch-driven thymocyte differentiation and leukemia. J Exp Med 2012; 209: 713–728.
Liedtke M, Cleary ML . Therapeutic targeting of MLL. Blood 2009; 113:6061–6068.
Daigle SR, Olhava EJ, Therkelsen CA, Majer CR, Sneeringer CJ, Song J et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 2011; 20: 53–65.
Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan WI et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 2011; 478: 529–533.
Craddock C, Quek L, Goardon N, Freeman S, Siddique S, Raghavan M et al. Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia. Leukemia 2013; 27: 1028–1036.
Smith BD, Beach CL, Mahmoud D, Weber L, Henk HJ . Survival and hospitalization among patients with acute myeloid leukemia treated with azacitidine or decitabine in a large managed care population: a real-world, retrospective, claims-based, comparative analysis. Exp Hematol Oncol 2014; 3: 10.
Gu Y, Lindner J, Kumar A, Yuan W, Magnuson MA . Rictor/mTORC2 is essential for maintaining a balance between beta-cell proliferation and cell size. Diabetes 2011; 60: 827–837.
Zhang Y, Hu T, Hua C, Gu J, Zhang L, Hao S et al. Rictor is required for early B cell development in bone marrow. PLoS One 2014; 9: e103970.
Somervaille TC, Cleary ML . Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell 2006; 10: 257–268.
Hua C, Guo H, Bu J, Zhou M, Cheng H, He F et al. Rictor/mammalian target of rapamycin 2 regulates the development of Notch1 induced murine T-cell acute lymphoblastic leukemia via forkhead box O3. Exp Hematol 2014; 42: 1031–1040, e1031-e1034.
Sarbassov DD, Guertin DA, Ali SM, Sabatini DM . Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307: 1098–1101.
Zhu X, He F, Zeng H, Ling S, Chen A, Wang Y et al. Identification of functional cooperative mutations of SETD2 in human acute leukemia. Nat Genet 2014; 46: 287–293.
Laplante M, Sabatini DM . mTOR signaling in growth control and disease. Cell 2012; 149: 274–293.
Chen CC, Jeon SM, Bhaskar PT, Nogueira V, Sundararajan D, Tonic I et al. FoxOs inhibit mTORC1 and activate Akt by inducing the expression of Sestrin3 and Rictor. Dev Cell 2010; 18: 592–604.
Guertin DA, Stevens DM, Saitoh M, Kinkel S, Crosby K, Sheen JH et al. mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 2009; 15: 148–159.
Chen C, Liu Y, Liu R, Ikenoue T, Guan KL, Liu Y et al. TSC-mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen species. J Exp Med 2008; 205: 2397–2408.
Ito K, Bernardi R, Morotti A, Matsuoka S, Saglio G, Ikeda Y et al. PML targeting eradicates quiescent leukaemia-initiating cells. Nature 2008; 453: 1072–1078.
Takeishi S, Matsumoto A, Onoyama I, Naka K, Hirao A, Nakayama KI . Ablation of Fbxw7 eliminates leukemia-initiating cells by preventing quiescence. Cancer Cell 2013; 23: 347–361.
Julien LA, Carriere A, Moreau J, Roux PP . mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling. Mol Cell Biol 2010; 30: 908–921.
Sykes SM, Lane SW, Bullinger L, Kalaitzidis D, Yusuf R, Saez B et al. AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. Cell 2011; 146: 697–708.
Sandhofer N, Metzeler KH, Rothenberg M, Herold T, Tiedt S, Groiss V et al. Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia. Leukemia 2015; 29: 828–838.
Lee K, Heffington L, Jellusova J, Nam KT, Raybuck A, Cho SH et al. Requirement for Rictor in homeostasis and function of mature B lymphoid cells. Blood 2013; 122: 2369–2379.
Cheng H, Zou Y, Ross JS, Wang K, Liu X, Halmos B et al. RICTOR amplification defines a novel subset of patients with lung cancer who may benefit from treatment with mTORC1/2 inhibitors. Cancer Discov 2015; 5: 1262–1270.
Acknowledgements
We thank Jiang J (Department of Developmental Biology, University of Texas Southwestern Medical Center at Dallas) for discussions and suggestions and Dr MA Magnuson from Vanderbilt University for providing the Rictorfl/fl mice. This work was supported in part by the ‘863’ Program (2012AA02A507) and ‘973’ Program (2012CB966604) of the China Ministry of Science and Technology; National Natural Science Funds of China (81025011, 81230052, 81090414, 81572565, 81500137).
Author contributions
Conception and design: Y Fang, Y Yang, JF Zhou. Development of methodology: Y Fang, Y Yang, CL Hua, M Zhou. Acquisition of data: Y Fang, Y Yang, CL Hua, SM Xu, HD Guo, N Wang, H Cheng. Analysis and interpretation of data (for example, statistical analysis, flow cytometry interpretation): Y Fang, Y Yang, CL Hua, SM Xu, XJ Zhao, L Huang, F Yu. Writing, review and/or revision of the manuscript: Y Fang, Y Yang, JF Zhou. Administrative, technical or material support: L Meng, T Cheng, Michael L Wang. Study supervision: WP Yuan, D Ma, JF Zhou.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Rights and permissions
About this article
Cite this article
Fang, Y., Yang, Y., Hua, C. et al. Rictor has a pivotal role in maintaining quiescence as well as stemness of leukemia stem cells in MLL-driven leukemia. Leukemia 31, 414–422 (2017). https://doi.org/10.1038/leu.2016.223
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2016.223